Literature DB >> 22649199

CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.

Amy J Beres1, Dipica Haribhai, Alexandra C Chadwick, Patrick J Gonyo, Calvin B Williams, William R Drobyski.   

Abstract

Regulatory T cells (Tregs), in particular CD4(+) Foxp3(+) T cells, have been shown to play an important role in the maintenance of tolerance after allogeneic stem cell transplantation. In the current study, we have identified a population of CD8(+) Foxp3(+) T cells that are induced early during graft-versus-host disease (GVHD), constitute a significant percentage of the entire Treg population, and are present in all major GVHD target organs. These cells expressed many of the same cell surface molecules as found on CD4(+) Tregs and potently suppressed in vitro alloreactive T cell responses. Induction of these cells correlated positively with the degree of MHC disparity between donor and recipient and was significantly greater than that observed for CD4(+)-induced Tregs (iTregs) in nearly all tissue sites. Mice that lacked the ability to make both CD8(+) and CD4(+) iTregs had accelerated GVHD mortality compared with animals that were competent to make both iTreg populations. The absence of both iTreg populations was associated with significantly greater expansion of activated donor T cells and increased numbers of CD4(+) and CD8(+) T cells that secreted IFN-γ and IL-17. The presence of CD8(+) iTregs, however, was sufficient to prevent increased GVHD mortality in the complete absence of CD4(+) Tregs, indicating at least one functional iTreg population was sufficient to prevent an exacerbation in GVHD severity, and that CD8(+) iTregs could compensate for CD4(+) iTregs. These studies define a novel population of CD8(+) Tregs that play a role in mitigating the severity of GVHD after allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22649199      PMCID: PMC3381996          DOI: 10.4049/jimmunol.1200886

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors.

Authors:  Bevra H Hahn; Ram Pyare Singh; Antonio La Cava; Fanny M Ebling
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

2.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

Authors:  Brygida Bisikirska; John Colgan; Jeremy Luban; Jeffrey A Bluestone; Kevan C Herold
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

3.  Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-28       Impact factor: 11.205

4.  In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance.

Authors:  Dela Golshayan; Shuiping Jiang; Julia Tsang; Marina I Garin; Christian Mottet; Robert I Lechler
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

5.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.

Authors:  Kathrin Rieger; Christoph Loddenkemper; Jochem Maul; Thomas Fietz; Daniel Wolff; Harald Terpe; Beate Steiner; Erika Berg; Stephan Miehlke; Martin Bornhäuser; Thomas Schneider; Martin Zeitz; Harald Stein; Eckhard Thiel; Rainer Duchmann; Lutz Uharek
Journal:  Blood       Date:  2005-11-08       Impact factor: 22.113

6.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

7.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.

Authors:  Emmanuel Zorn; Haesook T Kim; Stephanie J Lee; Blair H Floyd; Despina Litsa; Sankari Arumugarajah; Roberto Bellucci; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

8.  L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.

Authors:  Patricia A Taylor; Angela Panoskaltsis-Mortari; Jessica M Swedin; Philip J Lucas; Ronald E Gress; Bruce L Levine; Carl H June; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2004-08-03       Impact factor: 22.113

9.  Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation.

Authors:  Emmanuel Xystrakis; Anne S Dejean; Isabelle Bernard; Philippe Druet; Roland Liblau; Daniel Gonzalez-Dunia; Abdelhadi Saoudi
Journal:  Blood       Date:  2004-07-22       Impact factor: 22.113

10.  Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens.

Authors:  Isabelle J Suffia; Stacie K Reckling; Ciriaco A Piccirillo; Romina S Goldszmid; Yasmine Belkaid
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

View more
  51 in total

1.  Phenotypic and functional characteristic of a newly identified CD8+ Foxp3- CD103+ regulatory T cells.

Authors:  Ya Liu; Qin Lan; Ling Lu; Maogen Chen; Zanxian Xia; Jilin Ma; Julie Wang; Huimin Fan; Yi Shen; Bernhard Ryffel; David Brand; Francisco Quismorio; Zhongmin Liu; David A Horwitz; Anping Xu; Song Guo Zheng
Journal:  J Mol Cell Biol       Date:  2013-07-15       Impact factor: 6.216

Review 2.  Recent advances in CD8+ regulatory T cell research.

Authors:  Yating Yu; Xinbo Ma; Rufei Gong; Jianmeng Zhu; Lihua Wei; Jinguang Yao
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

3.  Working toward immune tolerance in lung transplantation.

Authors:  Xinguo Jiang; Mark R Nicolls
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

4.  Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.

Authors:  Ludovic Belle; Kimberle Agle; Vivian Zhou; Cheng Yin-Yuan; Richard Komorowski; Daniel Eastwood; Brent Logan; Jie Sun; Nico Ghilardi; Daniel Cua; Calvin B Williams; Melanie Gaignage; Reece Marillier; Jacques van Snick; William R Drobyski
Journal:  Blood       Date:  2016-08-03       Impact factor: 22.113

5.  CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice.

Authors:  Jessica Heinrichs; Jun Li; Hung Nguyen; Yongxia Wu; David Bastian; Anusara Daethanasanmak; M-Hanief Sofi; Steven Schutt; Chen Liu; Junfei Jin; Brian Betts; Claudio Anasetti; Xue-Zhong Yu
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 8.110

Review 6.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

7.  Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity.

Authors:  Li Zhang; Anne M Bertucci; Rosalind Ramsey-Goldman; Elizabeth Randall Harsha-Strong; Richard K Burt; Syamal K Datta
Journal:  Clin Immunol       Date:  2013-08-23       Impact factor: 3.969

8.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

9.  Antibody-suppressor CD8+ T Cells Require CXCR5.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Steven M Elzein; Christina L Avila; Robert T Warren; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2019-09       Impact factor: 4.939

Review 10.  Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.

Authors:  Anthony D Sung; Nelson J Chao
Journal:  Stem Cells Transl Med       Date:  2012-12-19       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.